The Asia Pacific Cancer Biomarkers Market would witness Market growth of 17.8% CAGR during the forecast period (2022-2028).
The utilization of RNA, DNA, microRNAs, and proteins in cancer detection involves molecular changes. To lessen the physical and emotional impact of cancer on patients and their families, governments in various nations are focused on investing in cancer prevention and early intervention. Additionally, governmental healthcare departments are actively involved in cancer research and therapy development. The rising incidence of cancer is predicted to spur innovation and advancement in the field of biomarker-based cancer diagnostics.
Due to an increase in the occurrence of different types of cancer such as prostate, breast, and lung cancer, the worldwide cancer biomarkers Market is predicted to develop significantly over the forecast period. Additionally, the rising importance of biological and targeted medicinal therapies, technical improvements, and the precision and reliability of cancer biomarkers all contribute to the Market 's growth. Additionally, increased government and public-private sector investments in cancer diagnostics R&D have a favorable impact on the industry. The cancer biomarkers Market is expected to benefit from advances in cancer research and a substantial unfulfilled need for cancer diagnostics.
The Asia Pacific witnessed increased usage of biomarker-based tests for cancer detection and the deployment of technologically sophisticated instruments by laboratories in the area. Additionally, increased funding and investments from public and private organizations in biomarker research and development, as well as the use of biomarkers in patient stratification and the medication development process, are expected to propel the Market in the area forward.
One of the top causes of death in Asian countries is cancer. In addition, the National Cancer Centre reported that three forms of blood malignancies (multiple lymphoma, malignant myeloma, and leukemia) accounted for some share of all cancers in Japan. After the United States and China, India has the world's third-highest number of blood cancer sufferers. The cancer rate has risen dramatically in recent decades and is anticipated to continue to rise substantially during the prediction period. Other important Market drivers include a more efficient drug delivery mechanism, non-invasive technologies, and higher survival rates. On the other side, the Market is hampered by the significant cost of diagnosis & products, reimbursement concerns, and the necessity for quick processing.
The China Market dominated the Asia Pacific Cancer Biomarkers Market by Country in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $2,797 million by 2028. The Japan Market is experiencing a CAGR of 17.1% during (2022 - 2028). Additionally, The India Market would exhibit CAGR of 18.6% during (2022 - 2028).
Based on Profiling Technologies, the Market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. Based on Application, the Market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. Based on Type, the Market is segmented into Protein, Genetic, and Others. Based on Cancer Type, the Market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin's Lymphoma, Prostate Cancer, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Cancer Biomarkers Market is Projected to reach USD 34.3 Billion by 2028, at a CAGR of 16.8%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.
By Profiling Technologies
By Application
By Type
By Cancer Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
